Spreadsheets are everywhere in pharmaceutical and life sciences organizations. Clinical trial data, raw material testing results, manufacturing logs, assay calculations, training records, the list goes on. Studies consistently show that spreadsheets are used to support GxP-critical processes at most pharma and biotech companies, often without formal controls, validated audit trails, or access restrictions.
That has always been a compliance risk. In 2026, it is also an AI readiness problem. And the two are converging at exactly the moment FDA enforcement is intensifying.
| FY2024 saw the highest FDA warning letter volume in five years. Data integrity was the leading citation category. And the most common source of data integrity failures in regulated environments is the uncontrolled spreadsheet. |
The compliance problem with spreadsheets is not theoretical
The FDA's 2018 Data Integrity and Compliance with Drug cGMP Guidance makes clear that electronic records used to support GxP decisions must meet ALCOA+ principles. Spreadsheets used without controls fail on multiple dimensions.
The audit trail gap
A standard Excel file has no audit trail. When a value is overwritten, the previous value is gone. There is no record of who made the change, when they made it, or what the original value was. FDA inspectors examining data integrity will ask to see the audit trail for a critical calculation or test result. If the answer is a spreadsheet with no controls, that is a finding.
The formula modification risk
Formulas in uncontrolled spreadsheets can be modified without detection. A scientist or analyst can change a calculation that affects a batch release decision, a clinical trial result, or a QC acceptance criterion, and there is no record that it happened.
The access control problem
Shared network spreadsheets are accessible to anyone with folder access. There is no restriction on who can open, edit, or save over a file. This violates the basic principle that access to GxP data should be limited to authorized personnel.
| FDA FINDING PATTERN |
|---|
| Warning letters frequently cite failure to have adequate controls over spreadsheets used to support predicate rules. Common language: 'your firm failed to establish and follow appropriate written procedures to prevent unauthorized access or changes to data.' |
The AI readiness dimension
FDA's 2025 AI Draft Guidance explicitly requires that training data for GxP AI models be accurate, complete, and traceable. Spreadsheet data with no audit trail, no access controls, and no input validation cannot be used as training data for a GxP AI model. Organizations that want to build AI capabilities on lab and manufacturing data need to fix the data layer first.
FDA's 2026 CSA Guidance reinforces this: spreadsheets used in GxP processes are computerized systems that need risk-proportionate validation. An uncontrolled, unvalidated spreadsheet in a high-impact GxP application is not just a data integrity risk, it is a system validation gap.
How CIMCON solves the spreadsheet compliance problem
CIMCON offers two complementary products that address spreadsheet compliance without requiring migration away from Excel. Both are deployed by hundreds of pharmaceutical and life sciences organizations across more than 30 countries.
| eInfotree Excel Desktop part11solutions.com/einfotree-excel-module-2/ |
|---|
Part 11 controls overlaid on existing spreadsheets, no migration, no disruption, and no change to user experience.
|
| XLValidator part11solutions.com/excel-validation-tool/ |
|---|
AI-enabled audit trail review that reads the spreadsheet change history and classifies anomalies by risk category.
|
Together, eInfotree Excel Desktop and XLValidator address both dimensions of the spreadsheet problem: eInfotree creates the controlled, ALCOA+-compliant record; XLValidator makes the AI-enabled review of that record practical at scale.
The bottom line
The spreadsheet data integrity problem is older than AI. The FDA has been issuing guidance on electronic records since 1997. But the stakes are higher now than they have ever been, rising warning letter volumes and the requirement that GxP AI applications be built on traceable, ALCOA+-compliant data.
Organizations that address spreadsheet compliance now get two things: a cleaner compliance posture for inspections that are becoming more frequent and rigorous, and a data foundation that makes AI-enabled quality improvement genuinely possible.
| The spreadsheet is not going away. The question is not whether to use spreadsheets in GxP processes, it is whether those spreadsheets are controlled to the standard that 2026 compliance and AI readiness both require. |